Vizage Aesthetic Center.
1470 Northwest 107th Avenue · Doral, FL 33172
4.9(822 Google reviews · 92 in past year)
Accepts insurance
Listing updated Oct 2, 2026
Aromas Medspa at Doral
Aromas Medspa at Doral · 9831 Northwest 58th Street · Doral, FL 33178
4.8· 686 Google reviews
Listing updated October 2, 2026
Retatrutide outlook for this practice
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
About this practice
Aromas Medspa at Doral is a medical spa in Doral, Florida. Its website describes personalized services including laser hair removal, skin rejuvenation, injectables and body treatments, names George Herrera, MD, and dates the practice to 2008. The listing also includes hormone therapy. On Google it holds a 4.8-star rating across 686 reviews dating back to 2021, with 47 in the past year, and reviewers most often mention the team's knowledge and the staff.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
★ 4.8
Google rating · 686 reviews
47
reviews in the past year (avg ★ 4.6)
Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-25. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★4.8 across 686 Google reviews. Of the 100 reviews we analyzed, 92 (92%) are positive (4–5★) and 8 (8%) are negative (1–2★).
What patients like
- Knowledgeable, professional providers30 reviews
- Friendly, helpful staff27 reviews
- Weight-loss results11 reviews
- Feeling listened to11 reviews
Common complaints
Very few complaints — only 8 negative reviews, with no recurring theme.
5★
90
4★
2
3★
0
2★
2
1★
6
Most recent Google reviews
Michele L.★★★★★2026-09-25Great service ! I have doing my Botox treatment for over a 1 year now with Dr. Alberto , and I’m so happy with the results every time . Thanks Aroma Med spa . You guys are the best !
Vivi G.★★★★★2026-09-25Todos los tratamientos que me he realizado han sido un éxito! Son súper profesionales y amables.
Naiviv R.★★★★★2026-09-19Alison del front desk y Maidelis fueron muy atentas y profesionales . Muy buen servicio en general
Mariela R.★★★★★2026-09-18Muy recomendado sindy es la mejor es muy amable y muy pasiente Ella se toma su tiempo y explica todo con detalles.
HILMA I.★★★★★2026-09-17I love this place, the service is top tier. They have all types of services and greet you with a warm welcome as soon as you come in. I recommend this place to anyone.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Nearby providers in Doral
Accepts insurance
Listing updated Oct 2, 2026
Luminer Wellness & Medspa
8175 Northwest 12th Street · Doral, FL 33126
5.0(91 Google reviews · 88 in past year)
Accepts insurance
Listing updated Oct 2, 2026
FaceBeauty Med Spa
10305 Northwest 41st Street · Doral, FL 33178
5.0(308 Google reviews · 13 in past year)
Accepts insuranceSemaglutide todayTirzepatide today
Listing updated Oct 2, 2026
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs